What question did this study set out to answer?

To review the pharmacodynamics, mechanism of action, safety profile, administration techniques, and clinical efficacy of off-label intralesional bleomycin across a range of dermatologic disorders.

July 4, 2008Dermatologic Surgery

Bleomycin in Dermatology: A Review of Intralesional Applications

View Full Paper

Ask AI

Bookmark

Authors

PSPeter Saitta KKKarthik KrishnamurthyThomas Jefferson University LBLance Brown

Discussion

Member takes

Implication

Clinical review demonstrates the efficacy and safety of off-label intralesional bleomycin in diverse skin conditions, highlighting its utility as a primary or adjunctive therapy.

Key Points

To review the pharmacodynamics, mechanism of action, safety profile, administration techniques, and clinical efficacy of off-label intralesional bleomycin across a range of dermatologic disorders.
Narrative synthesis evaluating published literature on intralesional bleomycin administration for cutaneous conditions, including warts, vascular malformations, and cutaneous malignancies.
Review of clinical dosages, injection techniques, pharmacodynamic mechanisms, and available comparative data from randomized trials.
Intralesional bleomycin shows favorable efficacy and safety across recalcitrant warts, hemangiomas, vascular anomalies, telangiectasias, and cutaneous malignancies.
Evidence from randomized placebo-controlled trials comparing intralesional bleomycin against other standard local therapies remains limited.
Given its practical accessibility, safety profile, and therapeutic performance, intralesional bleomycin serves as a viable primary or adjunctive intervention in dermatology.

Cite This Study

Saitta et al. (2008) studied this question.

synapsesocial.com/papers/6a92531bb6e367a95b6c52f5 https://doi.org/10.1111/j.1524-4725.2008.34281.x

View Full Paper

Ask AI

Bookmark

July 4, 2008Dermatologic Surgery

Bleomycin in Dermatology: A Review of Intralesional Applications

View Full Paper

Ask AI

Bookmark

Authors

PSPeter Saitta KKKarthik KrishnamurthyThomas Jefferson University LBLance Brown

Discussion

Member takes

Implication

Clinical review demonstrates the efficacy and safety of off-label intralesional bleomycin in diverse skin conditions, highlighting its utility as a primary or adjunctive therapy.

Key Points

To review the pharmacodynamics, mechanism of action, safety profile, administration techniques, and clinical efficacy of off-label intralesional bleomycin across a range of dermatologic disorders.
Narrative synthesis evaluating published literature on intralesional bleomycin administration for cutaneous conditions, including warts, vascular malformations, and cutaneous malignancies.
Review of clinical dosages, injection techniques, pharmacodynamic mechanisms, and available comparative data from randomized trials.
Intralesional bleomycin shows favorable efficacy and safety across recalcitrant warts, hemangiomas, vascular anomalies, telangiectasias, and cutaneous malignancies.
Evidence from randomized placebo-controlled trials comparing intralesional bleomycin against other standard local therapies remains limited.
Given its practical accessibility, safety profile, and therapeutic performance, intralesional bleomycin serves as a viable primary or adjunctive intervention in dermatology.

Cite This Study

Saitta et al. (2008) studied this question.

synapsesocial.com/papers/6a92531bb6e367a95b6c52f5 https://doi.org/10.1111/j.1524-4725.2008.34281.x

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark